Stock fact sheet · data as of

TELA Bio, Inc. (TELA): fair value, margin of safety and Wheel Score

Healthcare · Medical - Devices · United States · Speculative / Distressed

Close1.10
GLS fair value1.191 of 9 models
Margin of safety+8%price below fair value
Wheel Score36Weakout of 100
Health3/9Piotroski F-score
Moat2.0/10GLS 10-year score
Market cap$49M108k shares a day
Implied vol.125%near-the-money, 20-60 d
P/E-EPS -0.72
Dividend yieldnone
Beta1.36moves more than the market
Next earnings12 Nov 2026in 27 days

Is TELA undervalued?

At 1.10 (close of 16 Oct 2026), TELA trades within a few percent of the GLS average fair value of 1.19 (8.2% below fair value). 1 models produced a value and they split 1 above the price to 0 below. A stock priced at fair value earns about half of the Wheel Score's Value points; the rest of the score comes from health, moat, premium and stability.

Only 1 of the nine models produced a value (DCF); the others need a dividend, positive free cash flow or positive book value the company does not have yet, so the average rests on a narrow base.

The nightly engine files TELA under Speculative / Distressed - negative earnings or a Piotroski score of 3 or less - which caps its Wheel Score at 45 and keeps it out of the Sunday Scan.

Nine valuation models for TELA

Each model turns the latest filed numbers into a value per share; the GLS fair value is the simple average of the ones that produce a positive number. The last two rows are shown for reference and never enter the average. The Quote page lets you switch any model off and add your own margin of safety.

ModelValuevs priceWhat it measures
DCF1.19+9%Present value of the projected free cash flows, discounted at the cost of capital
Graham Number--The most a defensive investor pays for the earnings and book value per share; no value tonight
Graham Growth--Graham's growth formula: EPS × (8.5 + 2 × growth), adjusted for bond yields; no value tonight
Lynch--EPS × the earnings growth rate (PEG of 1), growth capped at 25%; no value tonight
GLS Growth--EPS compounded ten years at the blended growth rate, discounted back at 15% a year; no value tonight
10 Cap--Owner's earnings (operating cash flow less maintenance capex) capitalised at 10%; no value tonight
Payback Time--Eight years of compounded free cash flow: the price at which the business pays for itself; no value tonight
DDM--Dividend discount model: next year's dividend ÷ (10% − 3% growth); needs a dividend; no value tonight
EPV--Earnings power value: current EPS capitalised at 9% with no growth; no value tonight
Zombie (liquidation)0.0105-99%Current assets less all liabilities, per share: the balance-sheet floor. Not in the average
Wall St target2.00+83%Analysts' average 12-month price target. Not in the average

Quality and financial health

Financial health is weak: TELA passes 3 of the nine Piotroski tests. Our screens drop the stock at the health rule; a low score is often the reason a stock looks cheap on the valuation models. The GLS Moat score is low at 2.0 out of 10, which says the ten-year record of revenue, earnings, margins and returns on capital has been inconsistent - growth and shocks rather than steady compounding.

Returns on capital are thin or negative - ROIC -62.7%, ROE -615.1%, ROA -47.7% - with debt at 8.82 times equity and negative free cash flow. Debt of 8.82 times equity is on the high side for the sector and is worth checking against the cash flow before treating the stock as a long-term hold.

TELA Bio, Inc. pays no dividend, so the DDM model does not apply and a covered-call holder earns only the premium and any price gain.

Institutional ownership scores 6/10, insider activity 10/10 and Congressional trading 5/10 on the GLS smart-money scales; the last recorded insider buy was on 15 Sep 2026.

Piotroski F-score3 / 9ROIC-62.7%
GLS Moat2.0 / 10ROE-615.1%
Debt / equity8.82ROA-47.7%
Free-cash-flow yield-64.0%Payout ratio0%
Institutions6 / 10Insiders · Congress10 · 5 / 10

Wheel Score 36: Weak

TELA scores 36 out of 100 on the Wheel Score, in the Weak band (under 50). Value 16/25, Health 7/20, Moat 3/15, Premium 5/20, Stability 6/20. The score is not a judgement on the company; it says the price, quality and premium do not line up for selling puts on it today.

Implied volatility is 125%, far above the range the wheel strategy is built for. The premium looks generous; the Wheel Score gives it only 5 of 20 Premium points because moves of that size can blow through any strike. Chain open interest is thin - 232 contracts across every expiry - so fills at a fair price are not guaranteed; a 30-45-day put may not exist at a usable strike.

Volume runs at 108k shares a day on a market cap of $49M, with a beta of 1.36 - a high beta, so the stock tends to move more than the market and a strike can be gapped through; the Stability part of the Wheel Score gives that 6 of 20.

PartPointsFrom
Value16 / 258% margin of safety
Health7 / 20Piotroski 3/9
Moat3 / 15moat 2.0/10
Premium5 / 20implied volatility 125%
Stability6 / 20108k shares/day, $49M cap, beta 1.36

The Wheel Score ranks ~7,400 US stocks for selling cash-secured puts and covered calls; it is updated nightly and is not a recommendation. The walkthrough lesson shows how the score fits into a trade, start to finish.

Upcoming events

The next earnings report is due on 12 Nov 2026, 27 days away; a 30-45-day put sold today would expire after it, which is worth weighing against the premium.

Earnings, dividend, IPO, split and economic calendars for the whole market, filterable to your watchlists.

Similar stocks in Medical - Devices

The 12 companies below are the closest to TELA Bio, Inc. by market cap within the Medical - Devices industry, each with its own fact sheet; the Compare page puts up to eight of them side by side.

StockCloseFair valueMoSWheelMkt cap
POSC
Positron Corporation
1.50--22No options$49M
COCH
Envoy Medical, Inc.
0.64470.0239-2603%11No options$50M
MYO
Myomo, Inc.
1.30--31Weak$51M
SRTS
Sensus Healthcare, Inc.
2.863.03+6%36Weak$47M
XTNT
Xtant Medical Holdings, Inc.
0.31850.2440-31%16No options$45M
SNWV
SANUWAVE Health Inc.
5.1434.46+85%39No options$44M
NNOX
Nano-X Imaging Ltd.
0.4911--31Weak$39M
MBOT
Microbot Medical Inc.
0.95000.0728-1205%25Weak$64M
RPID
Rapid Micro Biosystems, Inc.
0.8173--24No options$37M
CVRX
CVRx, Inc.
1.39--36Weak$37M
QTI
QT Imaging Holdings, Inc.
2.50--32No options$37M
HYPR
Hyperfine, Inc.
0.7801--42Weak$71M

⚖ Compare TELA with 7 of them   All Healthcare stocks →

Screen the whole market the same way

A free GLS Equity account gets you nightly fair value and the Wheel Score on ~7,400 US stocks, a watchlist, the scanner preview and the Sunday Scan - the same eight-rule screen, emailed every week. Pro adds the full put and call scanners, unlimited watchlists with alerts and the trade journal.

Start free See the Sunday Scan

Questions about TELA

Is TELA undervalued right now?

Not meaningfully: at 1.10 the stock trades within a few percent of the GLS average fair value of 1.19 (8.2% below fair value, data as of 16 Oct 2026).

What is the Wheel Score of TELA and what does it mean?

TELA scores 36 out of 100 (Weak). The Wheel Score blends the margin of safety (25 points), Piotroski health (20), the GLS moat (15), the option premium on offer (20) and trading stability (20) into one number that ranks stocks for the wheel strategy - selling cash-secured puts, then covered calls if assigned. 80 and above is Prime, 65-79 Good, 50-64 Fair, under 50 Weak.

What is the GLS fair value for TELA?

1.19 per share as of 16 Oct 2026 - the simple average of the 1 valuation models (out of nine: DCF, Graham Number, Graham Growth, Lynch, GLS Growth, 10 Cap, Payback Time, DDM and EPV) that produced a positive value. The models run every night on the latest filings; the Quote page lets you switch any of them off and add a margin of safety of your own.

When does TELA Bio, Inc. report earnings next?

The next earnings report is due on 12 Nov 2026, 27 days from the data date of 16 Oct 2026. The Calendars page lists every upcoming report with its time of day.

Does TELA have listed options, and how liquid are they?

Yes. The nightly snapshot found 30 listed contracts with 232 open interest across all expiries and implied volatility of 125% on the near-the-money contracts. The Options scanner lists the cash-secured put and covered call set-ups with premium and annualised yield worked out.

Data as of 16 Oct 2026: prices and fundamentals from Financial Modeling Prep, option data from Polygon; valuations, scores and the Wheel Score by GLS Equity's models, run nightly. Prices in USD; the close shown is the previous session's. Everything on this page is general information produced by automated models from third-party data - not a recommendation to buy, sell or trade any security or option, and not financial advice. Past performance is not indicative of future results. GLS Equity provides data and tools, not financial advice.